Corporate news

CLB Member, Novo Nordisk, Webinar: Taking a Different Direction in the Treatment of Primary Hyperoxaluria Type 1 (PH1) Genetic Kidney Diseases
June 13, 2025

June 27, 2025 Dr Prasad Devarajan is a pediatric nephrologist at the Cincinnati Children’s Hospital Medical Center. He specializes in pediatric acute kidney injury and kidney stone disease. He has authored more than 350 peer-reviewed publications, 100 book chapters, and delivered more than 250 invited lectures nationally and internationally. Dr…

Read More
A Message From our CLB Partner
September 9, 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy Sep 05, 2024 PDF Version FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term…

Read More